Avoro Capital Advisors MNKD Position
Active3-Fund ConvergenceAvoro Capital Advisors trimmed their position in MannKind Corporation (MNKD) in Q4 2025, holding $25.2M worth of shares across 4,444,444 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
MNKD is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Technosphere Insulin in 228 days (Nov 30, 2026), making the timing of Avoro Capital's position particularly relevant.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Full company profile →Short Interest
7.5%
3.0 days to cover
Avoro Capital Advisors MNKD Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 4,444,444 | -24,433 | $25.2M |
| Q3 2025 | Decreased | 4,468,877 | -1,381,123 | $24.0M |
| Q2 2025 | Decreased | 5,850,000 | -2,900,000 | $21.9M |
| Q1 2025 | Held | 8,750,000 | — | $44.0M |
| Q4 2024 | Held | 8,750,000 | — | $56.3M |
| Q3 2024 | Decreased | 8,750,000 | -9,524 | $55.0M |
| Q2 2024 | Decreased | 8,759,524 | -240,476 | $45.7M |
| Q1 2024 | Held | 9,000,000 | — | $40.8M |
| Q4 2023 | Held | 9,000,000 | — | $32.8M |
| Q3 2023 | Decreased | 9,000,000 | -100,000 | $37.2M |
| Q2 2023 | Held | 9,100,000 | — | $37.0M |
| Q1 2023 | New | 9,100,000 | +9,100,000 | $37.3M |
Frequently Asked Questions
Does Avoro Capital Advisors own MNKD?
Yes. As of Q4 2025, Avoro Capital Advisors holds 4,444,444 shares of MannKind Corporation (MNKD) valued at $25.2M. This data comes from their SEC 13F filing.
How many hedge funds own MNKD?
3 specialist biotech hedge funds currently hold MNKD, including EcoR1 Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy MNKD?
Avoro Capital Advisors's position in MNKD was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's MNKD position increasing or decreasing?
Avoro Capital Advisors trimmed their MNKD position in the most recent quarter, reducing by 24,433 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MNKDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →